Why the study?
While SGLT2 inhibitors improve survival and reduce adverse events in HFrEF, less is known about their role in promoting cardiac structure and function changes.
Does SGLT2 inhibitor therapy improve echocardiographic parameters of cardiac structure and function in patients with stable chronic HFrEF?
Population
151 consecutive patients with stable chronic HFrEF
Comparison
Cardiac parameters before vs after 6 months of SGLT2i treatment
Design
Prospective multicenter observational cohort study
Follow-up
6 months
Key result
Six months of SGLT2 inhibitor therapy in ambulatory patients with HFrEF significantly increased mean ejection fraction from 32% to 35% (P<0.001) and improved left ventricular volumes.
Authors
Loading...
Associated with LVEF improvement and reverse remodeling in HFrEF; extends outcome data but leaves open causality and practice change.
Cohort (n=151)
Yes
Does SGLT2 inhibitor therapy improve echocardiographic parameters of cardiac structure and function in patients with stable chronic HFrEF?
Absolute Event Rate: 35% vs 32%
p-value: p=< 0.001
SGLT2 inhibitors significantly improve left ventricular ejection fraction and promote favorable reverse remodeling of ventricular and atrial volumes over 6 months in real-world patients with HFrEF.
Angelis et al. (2025) conducted a cohort in heart failure with reduced ejection fraction (HFrEF) (n=151). SGLT2 inhibitors vs. Baseline was evaluated on mean ejection fraction (p=< 0.001). Six months of SGLT2 inhibitor therapy in ambulatory patients with HFrEF significantly increased mean ejection fraction from 32% to 35% (P<0.001) and improved left ventricular volumes.